The analyses and visuals on this site are for informational purposes only and do not constitute investment advice.

© 2026 Datafin Financial Data Analysis Systems. All rights reserved. · v2.0

Privacy PolicyTerms of UseCookie Policy

KROS FINANCIAL STATEMENTS

Keros Therapeutics Inc — balance sheet, income statement and cash flow trends

KROSKeros Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value itDuel
PriceFinancialsPeers

Income Statement

Quarterly progression — trailing-twelve-month values
RevenueNet Income to Owners
-200 M0200 M202120222023202420252026

Profit Funnel

Q2 2026 · TTM
Revenue33.2 M $Gross Profit14.2 M $ · 43%Operating Income-101.5 M $ · -306%Pre-tax Income-86.1 M $ · -259%Net Income to Owners-83.2 M $ · -251%

Percentages are relative to revenue.

Key Figures

YoY change
Revenue33.2 M $-85.7%
Gross Profit14.2 M $-93.9%
Operating Income-101.5 M $-32,621.8%
EBITDA-84.5 M $-289.9%
Net Income to Owners-83.2 M $-543.0%

No peer data is available for this stock.

Balance Sheet

Quarterly period-end values
Total AssetsTotal LiabilitiesEquity
0250 M500 M750 M202120222023202420252026

Capital Structure

Q2 2026
Total Assets287.6 M
  • Equity262.3 M $91%
  • Current Liabilities12.2 M $4%
  • Long-term Liabilities13.1 M $5%

Key Figures

YoY change
Total Assets287.6 M $-62.0%
Total Liabilities25.3 M $-49.9%
Total Equity262.3 M $-62.9%
Cash & ST Investments257.6 M $-62.7%
Total Debt15.7 M $-12.4%
Net Debt-241.9 M $—

No peer data is available for this stock.

Cash Flow Statement

Quarterly progression — trailing-twelve-month values
Operating Cash FlowCapital ExpendituresFree Cash Flow
-100 M0100 M202120222023202420252026

Cash Flow Bridge

Q2 2026 · TTM
-400 M-200 M0-48 M $Operating-494 K $Investing-384.1 M $Financing-432.6 M $Net Change

Key Figures

YoY change
Operating Cash Flow-48 M $-187.2%
Capital Expenditures494 K $-74.8%
Free Cash Flow-48.5 M $-191.3%
Dividends Paid——

No peer data is available for this stock.

Amounts are in the company’s reporting currency. Peer comparison tables use ratio-based metrics so currency differences do not distort the picture.

Go deeper on KROS

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Sep 11, 26. This content is for informational purposes only and is not investment advice.